NCT05746104View on ClinicalTrials.gov

Second Window Indocyanine Green for All Nervous System Tumors

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

February 15, 2027

Study Completion Date

February 15, 2027

Conditions
Nervous System Tumor
Interventions
DRUG

Administration of Indocyanine Green (ICG) and Visualization of Tumor

A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.

Trial Locations (1)

19107

Pennsylvania Hospital, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER